

Table 1: Baseline characteristics of the 201 patients with migraine without aura who were enrolled in the study and randomized into the ergotamine-based medication group or the sumatriptan group.

Variable	group A n: 98	group B n: 103	test used, significance
Age (years): mean \pm SD	41.16 \pm 11.78	40.90 \pm 9.78	t-test (186): -0.136, p: 0.8923
Sex: female/male (%)	82/16 (84 %/16 %)	86/17 (84 %/16 %)	chi-square: 0.003, p: 0.9500
Duration (years) of MWA before screening median (95 % CI)	8.00 (6.00-10.00)	10.00 (8.00-10.00)	Mann-Whitney U: 3612.50, z: 1.373, p: 0.1697
Number of attacks per month during the 6-month period before screening: mean \pm SD	2.082 (\pm 2.3393) median 1.000 (1-20)	1.830 (\pm 1.4074) median 1.000 (1-8)	Mann-Whitney U: 4566.00, z: 0.793, p: 0.4275
Percent of patients receiving prophylactic medication before screening	0	0	Not applicable

MWA: migraine without aura, group A: ergotamine-based medication group, group B: sumatriptan group, n: number, SD: standard deviation, CI: confidence intervals.